Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy.

ABSTRACT:

Importance

Although PCSK9 inhibitors (PCSK9i) were approved in 2015, their high cost has led to strict prior authorization practices and high copays, and use of PSCK9i in clinical practice has been low.

Objective

To evaluate patient access to PCSK9i among those prescribed therapy.

Design, setting, and participants

Using pharmacy transaction data, we evaluated 45 029 patients who were newly prescribed PCSK9i in the United States between August 1, 2015, and July 31, 2016.

Main outcomes and measures

The proportion of PCSK9i prescriptions approved and abandoned (approved but unfilled); multivariable analyses examined factors associated with approval/abandonment including payor, prescriber specialty, pharmacy benefit manager, out-of-pocket cost (copay), clinical dia

SUBMITTER: Navar AM 

PROVIDER: S-EPMC5963012 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature